Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Lumakras is the first KRAS inhibitor to reach the market, getting approval from the FDA for KRAS G12C-mutated NSCLC last May, after decades of fruitless research into the drug class.

At the moment there are two KRAS inhibitors on the market, Krazati and Amgen’s Lumakras (sotorasib), which are both approved as second-line monotherapies for KRAS G12C-mutated non-small cell ...

During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care. After being diagnosed with colon cancer, I learned ...

Life expectancy for people with metastatic or metastasized lung cancer is low. The 5-year survival rate for small cell lung cancer is 3%, and 8% for non-small cell lung cancer (NSCLC). 25-30% of ...